BioNTech is laying off 90 employees across its U.S. footprint as the company plots its future in a post-COVID market.
All entries for: Immune Diseases
August 7, 2025
BioNTech
Layoffs
Disease Area: Immune Diseases
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
50,001+ employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
50,001+ employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 30, 2025
Biogen
Negative Outlook
Cambridge, MA
5,001-10,000 employees
Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other health care costs will continue to be subject to political and societal pressures on a global basis. Additionally, our ability to set the price for our products varies significantly from country to country and, as a result, so can the price or reimbursement of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.
Disease Area: Immune Diseases, Multiple, Neurological Diseases
Drug Type: Biologic, Small Molecule
July 30, 2025
GSK
Negative Outlook
While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce net sales resulting from the Medicare programs and limit our ability to increase the prices that we charge for our drugs. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payors for our current and any future approved products. These reforms may affect future investments in our drug development, should the reforms affect our risk-benefit analysis of investing in a drug candidate. Some of these changes and proposed changes could result in reduced reimbursement rates or the elimination of dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results.
Disease Area: Immune Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
July 29, 2025
Incyte Corp
Negative Outlook
While there is currently significant uncertainty regarding the implementation of some of these reforms or the scope of amended or additional reforms, the implementation of reforms could significantly reduce net sales resulting from the Medicare programs and limit our ability to increase the prices that we charge for our drugs. Reforms or other changes to these payment systems may change the availability, methods and rates of reimbursements from Medicare, private insurers and other third-party payers for our current and any future approved products. These reforms may affect future investments in our drug development, should the reforms affect our risk-benefit analysis of investing in a drug candidate. Some of these changes and proposed changes could result in reduced reimbursement rates or the elimination of dual sources of payment, which could reduce the price that we or any of our collaborators or licensees receive for any products in the future, and which would adversely affect our business strategy, operations and financial results.
Disease Area: Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
July 28, 2025
Rocket Pharmaceuticals
Layoffs
Rocket Pharmaceuticals is laying off 30% of its workforce in a strategic realignment initiative that also involves focusing resources on its late-stage heart disease programs, the company announced July 24. A total of 80 employees at Rocket’s Cranbury, New Jersey, site will be affected, according to a Workers Adjustment and Retraining Notification (WARN) Act notice. The layoffs will start Oct. 23 and continue through the end of the year, as per the WARN posting, and will allow Rocket to reduce its 12-month cash burn by almost 25%.
Disease Area: Cardiology, Immune Diseases, Multiple, Rare Diseases
Drug Type: Biologic
July 25, 2025
Genentech
Layoffs
San Francisco, CA
10,001-50,000 employees
Genentech is letting go of 87 employees at its South San Francisco headquarters, the second round of layoffs at the Roche subsidiary this year.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
July 21, 2025
GSK
Layoffs
GSK is letting go of 150 employees in Cambridge, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Endpoints News reported that the London-based company plans to move manufacturing of its pneumococcal vaccine asset that uses its multiple antigen presenting system (MAPS) technology from Cambridge to Marietta, Pennsylvania.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
